the report was compiled by outside researchers who went into the fda�s own database of �serious adverse [medical-drug] events.�
.
�the kind of review being proposed does not, at least initially, appear to bring anything new or needed to is already a robust system of oversight,� mogulof said in the statement.
.
.
.